- The Centers for Medicare and Medicaid Services’ switch from the Hierarchical Condition Categories model V24 to the modernized V28 brings about an updated disease classification structure that aligns with current healthcare standards.
- V28 enhances the accuracy of Medicare Advantage payments, impacting conditions like diabetes and dementia.
- Under the new model, HCC categories rise from 86 to 115, with updated inclusion and exclusion criteria.
- The transition aligns closely with Adageis’s mission of revolutionizing patient care through innovative value-based care solutions, positioning the company for growth.
- Adageis aims to improve healthcare delivery by helping providers streamline operations and focus on delivering quality care by implementing its AI-centric ProActive Care Platform.
- A unique offering in the healthcare technology space, the ProActive Care Platform offers flexible integration, proactive efficiency and advanced predictive analysis capabilities.
Adageis is a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare systems and providers. The company is in support of the Centers for Medicare and Medicaid Services’ (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model, considering the increased accuracy it will bring to Medicare Advantage payments and its overall improved alignment with current healthcare standards.
The shift to V28 is being phased in over three years, as this gradual timeline offers healthcare providers and Medicare Advantage plans the opportunity to adapt to the details of the new…
NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN